These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29244141)

  • 1. Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients.
    Britt NS; Tirmizi S; Ritchie DJ; Topal JE; McManus D; Nizet V; Casabar E; Sakoulas G
    J Antimicrob Chemother; 2018 Mar; 73(3):764-767. PubMed ID: 29244141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis.
    Ruggero MA; Peaper DR; Topal JE
    Infect Dis (Lond); 2015 Jun; 47(6):379-84. PubMed ID: 25746601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
    Stryjewski ME; Lentnek A; O'Riordan W; Pullman J; Tambyah PA; Miró JM; Fowler VG; Barriere SL; Kitt MM; Corey GR
    BMC Infect Dis; 2014 May; 14():289. PubMed ID: 24884578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world use of telavancin in the treatment of osteomyelitis.
    Saravolatz LD; Cleveland KO; Rikabi K; Hassoun A; Reilly J; Johnson LB; Spak C; Valenti S; Szpunar S
    Diagn Microbiol Infect Dis; 2019 Oct; 95(2):185-190. PubMed ID: 31256939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016.
    Duncan LR; Smith CJ; Flamm RK; Mendes RE
    J Glob Antimicrob Resist; 2020 Mar; 20():118-123. PubMed ID: 31325617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections.
    Harting J; Fernandez F; Kelley R; Wiemken T; Peyrani P; Ramirez J
    Diagn Microbiol Infect Dis; 2017 Dec; 89(4):294-299. PubMed ID: 29137718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
    Rubinstein E; Lalani T; Corey GR; Kanafani ZA; Nannini EC; Rocha MG; Rahav G; Niederman MS; Kollef MH; Shorr AF; Lee PC; Lentnek AL; Luna CM; Fagon JY; Torres A; Kitt MM; Genter FC; Barriere SL; Friedland HD; Stryjewski ME;
    Clin Infect Dis; 2011 Jan; 52(1):31-40. PubMed ID: 21148517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains.
    Xiong YQ; Abdelhady W; Tang C'; Bayer AS
    J Antimicrob Chemother; 2016 Oct; 71(10):2890-4. PubMed ID: 27353467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telavancin.
    Lyseng-Williamson KA; Blick SK
    Drugs; 2009; 69(18):2607-20. PubMed ID: 19943710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus.
    McKinnell JA; Corman S; Patel D; Leung GH; Gordon LM; Lodise TP
    Clin Ther; 2018 Mar; 40(3):406-414.e2. PubMed ID: 29454592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
    Corey GR; Rubinstein E; Stryjewski ME; Bassetti M; Barriere SL
    Clin Infect Dis; 2015 Mar; 60(5):787-96. PubMed ID: 25472944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of telavancin in the treatment of MRSA infections in hospital.
    Bassetti M; Mikulska M; Righi E; Nicolini L; Viscoli C
    Expert Opin Investig Drugs; 2009 Apr; 18(4):521-9. PubMed ID: 19335280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus.
    Reyes N; Skinner R; Benton BM; Krause KM; Shelton J; Obedencio GP; Hegde SS
    J Antimicrob Chemother; 2006 Aug; 58(2):462-5. PubMed ID: 16735425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.
    Kidd JM; Sakon CM; Oleksiuk LM; Cies JJ; Pettit RS; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
    Hegde SS; Difuntorum S; Skinner R; Trumbull J; Krause KM
    J Antimicrob Chemother; 2009 Apr; 63(4):763-6. PubMed ID: 19155225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence.
    Forstner C; Dungl C; Tobudic S; Mitteregger D; Lagler H; Burgmann H
    Clin Microbiol Infect; 2013 Jul; 19(7):E291-7. PubMed ID: 23490021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
    Sandrock CE; Shorr AF
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteraemia.
    Chen SY; Hsueh PR; Chiang WC; Huang EP; Lin CF; Chang CH; Chen SC; Chen WJ; Chang SC; Lai MS; Chie WC
    J Infect; 2014 Sep; 69(3):259-65. PubMed ID: 24797078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.
    Arshad S; Huang V; Hartman P; Perri MB; Moreno D; Zervos MJ
    Int J Infect Dis; 2017 Apr; 57():27-31. PubMed ID: 28131729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.